Two Sigma Investments’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-82,610
| Closed | -$330K | – | 3785 |
|
|
2025
Q2 | $330K | Sell |
82,610
-5,483
| -6% | -$13.6K | ﹤0.01% | 2756 |
|
|
2025
Q1 | $80.2K | Buy |
88,093
+56,169
| +176% | +$77.9K | ﹤0.01% | 2990 |
|
|
2024
Q4 | $88.4K | Buy |
+31,924
| New | +$121K | ﹤0.01% | 2984 |
|
|
2024
Q2 | – | Sell |
-29,893
| Closed | -$229K | – | 3171 |
|
|
2024
Q1 | $229K | Sell |
29,893
-23,807
| -44% | -$131K | ﹤0.01% | 2661 |
|
|
2023
Q4 | $229K | Sell |
53,700
-14,400
| -21% | -$51.2K | ﹤0.01% | 2782 |
|
|
2023
Q3 | $286K | Sell |
68,100
-17,487
| -20% | -$89K | ﹤0.01% | 2507 |
|
|
2023
Q2 | $477K | Buy |
85,587
+20,087
| +31% | +$119K | ﹤0.01% | 2353 |
|
|
2023
Q1 | $375K | Buy |
65,500
+53,117
| +429% | +$140K | ﹤0.01% | 2321 |
|
|
2022
Q4 | $13K | Sell |
12,383
-800
| -6% | -$1.4K | ﹤0.01% | 2716 |
|
|
2022
Q3 | $35K | Buy |
+13,183
| New | +$47.7K | ﹤0.01% | 2344 |
|
|
2022
Q2 | – | Sell |
-10,916
| Closed | -$45K | – | 2717 |
|
|
2022
Q1 | $45K | Buy |
+10,916
| New | +$64.3K | ﹤0.01% | 2497 |
|
Two Sigma Investments's INZY Position: Q3 2025 in Review
Two Sigma Investments sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 82,610 shares — an estimated $330K sold.
Two Sigma Investments first reported a position in INZY in Q1 2022 and held it in 11 quarters. The position peaked at $477K in Q2 2023. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Two Sigma Investments reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Two Sigma Investments sold 82,610 Inozyme Pharma shares in Q3 2025, an estimated $330K.
- Two Sigma Investments first reported a position in Inozyme Pharma in Q1 2022 and held it in 11 quarters.
- Two Sigma Investments's Inozyme Pharma position peaked at $477K in Q2 2023.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Two Sigma Investments's 13F filing for Q3 2025, filed 14 Nov 2025.